A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
Recruiting · NCT06775275 · Interventional (participants receive a specific treatment) · Lead sponsor: The First Affiliated Hospital of Guangzhou Medical University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Resectable NSQ NSCLC
- Age 18-65 years
- male or female
- ECOG 0-1
- Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
- Subjects must have adequate pulmonary function for the intended pneumonectomy;
Exclusion criteria
- SCLC or SQ NSCLC
- previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- patients who have previously used anti-angiogenic drugs;
- allergic to any component of the study drug or chemotherapy drugs
- patients with any severe and or uncontrolled disease
Where it is running
1 location listed.
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University - Guangzhou, China